Pharmaceutical

China approves AstraZeneca-Daiichi Sankyo’s gastric cancer therapy

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), has received conditional approval in China for gastric cancer.

Aug 15, 2024 - 04:00
China approves AstraZeneca-Daiichi Sankyo’s gastric cancer therapy
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), has received conditional approval in China for gastric cancer.
Read the original article

Tags:

Previous Article

UAE approves BioArctic and Eisai’s Leqembi for Alzheimer’s disease

Next Article

Eli Lilly inaugurates R&D facility in Boston, US

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants clearance to Gilead Sciences’ sNDA for Veklury

FDA grants clearance to Gilead Sciences’ sNDA for Veklury

Aug 26, 2023

Opinion: How to save the U.S. News & World Report Best Hospitals rankings

Opinion: How to save the U.S. News & World Report Best ...

Aug 25, 2023

STAT+: Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year

STAT+: Nimbus Therapeutics raises $210 million in one o...

Sep 6, 2023